Medtronic PLC
medtronic.comWhat Do They Do?
Develops and sells medical devices and therapies for heart and blood-vessel conditions, neurological and spinal disorders, and surgical care to healthcare systems, clinicians, and patients.
10-K for FY2026, filed Jun 18, 2026We have three reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services…View ↗
The Cardiovascular Portfolio is made up of the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral…View ↗
NEUROSCIENCE PORTFOLIOView ↗
The Medical Surgical Portfolio includes the Surgical & Endoscopy and Acute Care & Monitoring divisions. Products and therapies of this…View ↗
How Do They Make Money?
Healthcare providers buy medical devices and therapies, generally paid for when products ship or are delivered; capital equipment is paid for at installation, while consigned products are paid for when used or implanted. Remote-monitoring and equipment-maintenance services are paid for over the service period.
10-K for FY2026, filed Jun 18, 2026
-
10-K for FY2026, filed Jun 18, 2026
FY2026 revenue by reportable segment ↗
$36.4B
-
10-K for FY2026, filed Jun 18, 2026
$36.4B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Reportable segment net sales
Mix
10-K for FY2026, filed Jun 18, 2026 |
91%
FY2023: 98%
|
Reportable segment net sales, FY2026
$33.1B Sources
|
Mix |
|
Diabetes
|
8.6%
FY2023: 7.2%
|
Diabetes, FY2026
$3.1B Sources
|
|
|
Other Operating Segments
|
0.4% |
Other Operating Segments, FY2026
$135M Sources
|
Who Are Their Customers?
Sells through its own sales representatives and independent distributors. Hospitals, clinics, physician offices, and other care providers use its products; group purchasing organizations and health networks negotiate supply contracts for member facilities.
10-K for FY2026, filed Jun 18, 2026We sell our medical devices and therapies through a combination of direct sales representatives and third parties (e.g., independent…View ↗
Our marketing and sales strategy is focused on rapid, cost-effective delivery of high-quality products to a diverse group of customers…View ↗
The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 13 cents of every revenue dollar as net income in FY2026 and turned 15 cents into free cash flow.
10-K for FY2026, filed Jun 18, 2026
$6.5BView ↗
10-K for FY2026, filed Jun 18, 2026
$4.8BView ↗
10-K for FY2026, filed Jun 18, 2026
$5.4BView ↗
How Are They Changing?
-
Sep 1, 2026
Raises FY27 revenue growth and earnings guidance
Raised organic revenue growth guidance to 7.25% to 7.75% and diluted non-GAAP EPS guidance to $5.94 to $6.00.
Sources
8-K, filed Sep 1, 2026
The company today raised its FY27 organic revenue growth and EPS guidance. The company raised its FY27 organic revenue growth guidance to…View ↗
Growing. Revenue grew 15% in 4 years, from $31.7B in FY2022 to $36.4B in FY2026, about 4% a year.
Diabetes business separation
The earlier report listed Diabetes as an operating and reportable segment. The latest says the Diabetes Business completed an initial public offering and is no longer considered a reportable segment.
10-K for FY2023, filed Jun 22, 2023 10-K for FY2026, filed Jun 18, 2026We have four operating and reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and…View ↗
We have three reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services…View ↗
Loading...
